How do doctors diagnose irritable bowel syndrome (IBS)?

IBS diagnosis begins with a careful conversation and focused evaluation—because there is no single test that proves irritable bowel syndrome. In this guide, you’ll learn how doctors assess IBS symptoms, apply recognized diagnostic criteria, and rule out other conditions that can look similar. You’ll also see where laboratory tests, imaging, and gut microbiome insights fit into the process. Understanding how IBS is diagnosed helps you navigate uncertainty, avoid unnecessary testing, and know when deeper analysis—such as stool microbiome profiling—can add meaningful context to your personal gut health.

Understanding IBS Diagnosis: A First Step Towards Gut Health

Irritable bowel syndrome (IBS) is a common functional bowel disorder characterized by abdominal pain related to bowel movements and changes in stool frequency or form. It affects an estimated 10–15% of people worldwide and can meaningfully impact daily life, productivity, and mental well-being. Reaching an accurate diagnosis matters: it clarifies what IBS is and is not, helps prevent excessive or unhelpful interventions, and guides realistic, personalized strategies for symptom management.

This article walks through the clinical reasoning behind IBS diagnosis—from symptom-based criteria and targeted tests to the role of the gut microbiome. It also explains why symptoms alone don’t reveal the root cause, and how selective testing, including microbiome analysis, can offer additional insight without over-promising or replacing medical evaluation.

Core Explanation of the Topic

What Is Irritable Bowel Syndrome?

IBS is a chronic disorder of gut–brain interaction (DGBI), previously called a functional gastrointestinal disorder. People with IBS typically experience abdominal pain, bloating or distension, and altered bowel habits (constipation, diarrhea, or a mix of both). Symptoms often fluctuate over time, with good and bad days, and may be influenced by stress, diet (such as fermentable carbohydrates), medications, hormones, and sleep patterns. IBS is subtyped based on predominant stool pattern: IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), mixed (IBS-M), or unclassified (IBS-U). Subtyping helps tailor management but does not change the underlying diagnostic approach.

Importantly, IBS is a positive clinical diagnosis—not just a label used when tests are “normal.” It’s identified by specific symptom patterns supported by a focused physical exam and targeted testing to exclude other conditions where appropriate. IBS is distinct from inflammatory bowel disease (IBD), celiac disease, infections, microscopic colitis, and structural problems like strictures or cancer. While many of these conditions can cause pain or bowel changes, they typically leave objective signs (inflammation, ulcers, lab abnormalities) that IBS does not.

Diagnostic Criteria for IBS

Clinicians commonly use the Rome criteria to diagnose IBS. The current Rome IV criteria define IBS as recurrent abdominal pain, on average, at least one day per week in the last three months, associated with two or more of the following: related to defecation, associated with a change in stool frequency, and associated with a change in stool form (appearance). Symptoms should have begun at least six months before diagnosis. Subtyping is based on the proportion of bowel movements with abnormal stool forms assessed by the Bristol Stool Form Scale.

IBS symptoms assessment includes a detailed history: timing, triggers, nocturnal symptoms, unintentional weight loss, rectal bleeding, family history (IBD, colorectal cancer, celiac disease), medication and antibiotic exposures, travel, and psychosocial factors. A brief, focused exam assesses for abdominal tenderness, masses, or signs of systemic disease. The purpose is not to “prove” IBS with a single measurement but to affirm the diagnostic criteria and identify any warning signs that merit further evaluation.

Why Diagnosing IBS Matters

A clear diagnosis helps patients and clinicians move from uncertainty to action. It reduces unnecessary emergency visits and invasive procedures, enables evidence-based dietary and behavioral strategies, and makes it easier to monitor change over time. Conversely, avoiding a diagnosis or endlessly testing “just in case” can delay helpful interventions, increase anxiety, and add cost without improving outcomes. IBS diagnosis also opens the door to broader gut health conversations, including how the microbiome, diet, stress, and sleep may interact to influence symptoms.

Why This Topic Matters for Gut Health

The Broader Context of Gut Wellness

Your gut is an ecosystem: immune cells, nerves, hormones, and trillions of microbes interact continuously. These systems affect not only digestion but also mood, metabolism, and immune balance. IBS sits at the intersection of these networks, with research pointing to changes in gut motility, visceral sensitivity (how strongly your nerves perceive gut sensations), mucosal immune activation, barrier function, and microbial composition. Understanding how IBS is diagnosed—beyond a list of symptoms—helps clarify which levers might matter in your case and why a personalized approach to gut wellness is often needed.

The Limitations of Symptom-Only Diagnosis

Symptoms are central to IBS diagnosis, but symptoms alone rarely pinpoint the root cause. Bloating, pain, diarrhea, or constipation can arise from diverse mechanisms: carbohydrate malabsorption, altered bile acid handling, intestinal dysbiosis, small intestinal bacterial or methanogen overgrowth, pelvic floor dysfunction, food intolerances, or low-grade inflammation, among others. Without context, symptom overlap can lead to misdiagnosis, overtreatment, or missed diagnoses such as IBD, celiac disease, or microscopic colitis. A thoughtful gastrointestinal health evaluation balances a positive clinical diagnosis of IBS with selective tests to rule out alternative explanations when indicated.

Related Symptoms, Signals, and Health Implications

Common IBS Symptoms and Their Variability

IBS commonly presents with:

• Recurrent abdominal pain related to bowel movements
• Altered stool form (loose or hard) and/or frequency
• Bloating or visible distension
• Sensation of incomplete evacuation, urgency, or straining
• Extra-intestinal symptoms such as fatigue, sleep disturbance, and anxiety, often reflecting gut–brain interplay

Symptoms vary widely between people and even within the same person over time. Some notice predictable food sensitivities (for example, lactose, high-FODMAP foods), while others find that stress or sleep disruption drives flares. It’s crucial to recognize signals that warrant further evaluation, including:

• Unintentional weight loss
• Rectal bleeding or black stools
• Persistent fever or recurrent nighttime diarrhea that wakes you from sleep
• Iron-deficiency anemia or abnormal inflammatory markers
• Onset after age 50 without prior IBS history
• Family history of IBD, colorectal cancer, or celiac disease

These “alarm features” do not mean IBS cannot be present, but they signal the need to exclude other diseases before settling on an IBS diagnosis.

Signals Beyond IBS: Ruling Out Other Conditions

Ruling out other conditions is not about testing everything—it’s about targeted evaluation guided by your history and exam. Depending on your presentation, clinicians may consider:

• Inflammatory bowel disease (Crohn’s disease, ulcerative colitis): Suggested by persistent diarrhea with blood, weight loss, fever, or elevated C-reactive protein (CRP). Fecal calprotectin can help distinguish inflammatory from functional symptoms.
• Celiac disease: Particularly in IBS-D or IBS-M. Screening typically uses tissue transglutaminase IgA (tTG-IgA) with total IgA; alternatives exist for IgA deficiency.
• Infectious etiologies: Stool testing may be warranted with acute onset, travel exposure, or post-antibiotic diarrhea (e.g., C. difficile testing).
• Microscopic colitis: Chronic watery diarrhea, often in middle-aged or older adults; requires colonoscopy with biopsies even when the mucosa looks normal.
• Bile acid malabsorption (BAM): Under-recognized cause of chronic diarrhea; specialized tests (SeHCAT where available, serum C4, or fecal bile acids) or an empiric therapeutic trial may be considered.
• Lactose or fructose intolerance: Hydrogen breath testing or structured elimination/challenge can clarify carbohydrate malabsorption.
• Small intestinal bacterial or methanogen overgrowth (SIBO/IMO): Consider in patients with risk factors (e.g., motility disorders, prior GI surgery) or refractory symptoms; breath testing has limitations and is interpreted with caution.
• Thyroid dysfunction: Hyperthyroidism can cause diarrhea; hypothyroidism can worsen constipation.
• Pancreatic exocrine insufficiency: Fatty stools and weight loss; fecal elastase can be helpful when suspected.
• Pelvic floor dyssynergia: Constipation with straining, splinting, or outlet difficulty; anorectal manometry and balloon expulsion testing may be indicated.
• Endometriosis or gynecologic conditions: Can mimic IBS with cyclical pain and bowel changes.
• Colorectal cancer: Screen according to age and risk; colonoscopy is recommended for alarm features or positive screening tests.

This stepwise approach is what makes IBS diagnosis both safe and efficient—focused enough to catch important conditions, measured enough to avoid a cascade of unnecessary procedures.

Individual Variability and Diagnostic Uncertainty

Why No Single Test Can Confirm IBS

IBS is defined by how you feel and function, not by a single biomarker. Its biology is multifactorial, involving neural, immune, epithelial, and microbial components that vary between individuals. Two people with identical symptoms might have different drivers—one primarily microbiome-related and fermentative gas production, another dominated by stress-related visceral hypersensitivity and altered motility. Because IBS is a syndrome, not a singular disease with one cause, a “yes/no test” is not realistic. Instead, diagnosis blends symptom criteria, clinical judgment, and selective exclusion of other diseases.

Uncertainty in Diagnosing Functional Bowel Disorders

Clinicians must balance two risks: missing a serious condition and over-testing that creates noise, anxiety, or false positives. Functional bowel disorder testing focuses on identifying red flags, applying Rome criteria, and using targeted labs or imaging when a specific alternative diagnosis is plausible. Shared decision-making is key: your goals, values, and tolerance for uncertainty shape whether to pursue additional tests now or monitor and reassess later. Over time, tracking symptom patterns alongside diet, stress, sleep, and menstrual cycles can reveal insights that a one-time test cannot.

Why Symptoms Alone Do Not Reveal the Root Cause

The Complexity of Gut Disorders

Gut symptoms arise from interconnected biology:

• Visceral hypersensitivity: Heightened nerve signaling makes normal amounts of gas or stool feel painful.
• Motility changes: Faster transit can cause diarrhea and urgency; slower transit can lead to constipation and bloating. Methane produced by intestinal archaea is associated with slowed motility in some individuals.
• Barrier and immune function: Subtle increases in intestinal permeability and mucosal immune activation (e.g., mast cells near nerves) may contribute to pain and sensitivity.
• Microbiome composition and metabolism: Differences in microbial diversity, fermentation patterns, and short-chain fatty acid (SCFA) production influence gas, pH, and motility, potentially affecting symptom severity.
• Bile acid signaling: Excess bile acids in the colon can drive watery stools and urgency; inadequate deconjugation or altered bile acid pools may contribute to constipation in others.
• Carbohydrate malabsorption: Poorly absorbed sugars and sugar alcohols can be rapidly fermented, leading to gas and distension.
• Gut–brain axis: Stress, anxiety, and sleep disturbance can modulate pain perception, motility, and immune tone via bidirectional neural and hormonal pathways.

Because multiple mechanisms can coexist, identical symptoms do not always share the same cause. That’s why thoughtful clinical assessment and, where appropriate, strategic testing help clarify your most relevant drivers.

The Role of Additional Testing in Clarifying Diagnosis

While IBS remains a clinical diagnosis, selective tests can strengthen diagnostic confidence and guide management. Potential evaluations include:

2-minute self-check Is a gut microbiome test useful for you? Answer a few quick questions and find out if a microbiome test is actually useful for you. ✔ Takes 2 minutes ✔ Based on your symptoms & lifestyle ✔ Clear yes/no recommendation Check if a test is right for me →

• Basic blood tests: Complete blood count (CBC) to assess for anemia; CRP to screen for systemic inflammation; thyroid-stimulating hormone (TSH) when thyroid disease is suspected.
• Celiac serology: tTG-IgA with total IgA in IBS-D or IBS-M, or when risk factors are present.
• Fecal calprotectin: Helps differentiate inflammatory conditions like IBD from functional disorders.
• Stool studies: For pathogens with acute onset or risk factors; C. difficile testing with recent antibiotic exposure; fecal elastase when pancreatic insufficiency is suspected.
• Breath tests: Hydrogen/methane for carbohydrate malabsorption; carefully selected SIBO/IMO breath tests in patients with risk factors or refractory symptoms.
• Bile acid assessment: Where available (SeHCAT, serum C4, fecal bile acids) or an empiric therapeutic trial in compatible cases.
• Colonoscopy: For alarm features, chronic diarrhea of unclear origin, or age-appropriate colorectal cancer screening; microscopic colitis requires biopsies even if mucosa appears normal.
• Anorectal physiologic testing: For refractory constipation with suspected pelvic floor dysfunction.
• Imaging or gynecologic evaluation: Based on clinical suspicion of structural or extra-intestinal causes.

This targeted approach supports a confident IBS diagnosis while ensuring other relevant conditions are not missed.

The Role of the Gut Microbiome in IBS

Understanding the Gut Microbiome’s Influence

The gut microbiome—bacteria, archaea, viruses, and fungi—shapes digestion, immunity, and nerve signaling. Microbes ferment dietary fibers and resistant starches to produce SCFAs (acetate, propionate, butyrate), which can nourish colon cells, modulate inflammation, and influence motility. Microbial metabolism also generates gases (hydrogen, methane, hydrogen sulfide) that alter gut sensation and transit. Through metabolites and cell–cell signaling, microbes interact with the enteric nervous system and immune cells, contributing to the gut–brain axis.

In IBS, studies frequently report differences in microbial diversity and composition compared with asymptomatic controls. Some individuals show reduced abundance of beneficial butyrate producers, shifts in Firmicutes and Bacteroidetes groups, or increased potential for gas production. These findings vary across studies and individuals, reflecting both methodological differences and genuine biological variability. As a result, the microbiome is increasingly recognized as a contributor—not the sole cause—of IBS for many people.

Microbiome Imbalances as a Contributing Factor

Dysbiosis refers to a departure from a balanced microbial ecosystem. Potential patterns relevant to IBS include:

• Lower microbial diversity: Sometimes associated with greater symptom instability and sensitivity, though not universally present.
• Altered fermentation profiles: Increased gas production can amplify distension and discomfort, especially in those with visceral hypersensitivity.
• Changes in SCFA production: Reduced butyrate-producing bacteria may influence barrier integrity and immune signaling in some individuals.
• Methanogen overabundance: Higher methane on breath testing is associated with slower transit and constipation in some people.
• Immune–microbe crosstalk: Subtle mucosal immune activation and mast cell proximity to nerves have been observed in subsets of IBS, potentially modulated by microbial signals.

It’s important to emphasize that these findings are correlations, not proofs of causation for every case. Still, they offer a biologically plausible framework for why certain dietary patterns, probiotics, and lifestyle measures help some individuals more than others—and why personalized data can be useful.

How Microbiome Testing Provides Insight into IBS

Advances in Microbiome Analysis

Microbiome testing typically involves stool analysis using DNA sequencing (e.g., 16S rRNA gene sequencing for bacterial profiles or shotgun metagenomics for higher-resolution taxonomy and functional potential). Some tests incorporate targeted qPCR for specific microbes, as well as markers reflecting inflammation, digestion, or microbial metabolites. While no stool microbiome test can diagnose IBS, these tools can contextualize symptoms by illuminating the microbial community’s composition and functional tendencies—information not captured by routine clinical labs.

Modern platforms can estimate microbial diversity, identify groups associated with butyrate production or gas formation, and provide indicators relevant to fiber fermentation, bile acid metabolism, and potential pathobionts. When interpreted carefully alongside clinical history and standard testing, microbiome analysis can refine hypotheses about triggers and guide more tailored interventions.

What a Microbiome Test Can Reveal in the Context of IBS

In an IBS workup, microbiome testing is best seen as an insight and education tool, not a diagnostic shortcut. Possible findings include:

• Microbial diversity: Broadly reflects ecosystem resilience; very low diversity may align with symptom variability or prior antibiotic exposure.
• Butyrate-producing bacteria: Relative abundance can hint at SCFA dynamics relevant to barrier and immune tone.
• Gas-associated microbes: Patterns suggestive of higher hydrogen or methane production potential, which may correlate with bloating or constipation tendencies.
• Opportunistic/pathobiont signals: Overrepresentation of certain taxa that may flourish after antibiotics or with dysbiosis, requiring nuanced interpretation.
• Functional pathways: Metabolic potential related to carbohydrate fermentation, bile acid transformation, and vitamin biosynthesis.

Such insights can inform practical choices—like which fibers to introduce slowly, whether to trial a low-FODMAP approach, or whether targeted probiotics/prebiotics make sense—always within the broader clinical picture. For readers curious about how structured stool microbiome analysis can complement standard care, see this overview of an at-home microbiome test. The goal is not to label or treat based on a single result, but to add a personalized lens to IBS management discussions.

Who Should Consider Microbiome Testing

Candidates for Gut Microbiome Evaluation

Microbiome testing is optional and not required for IBS diagnosis. It may be most useful for:

• People with chronic or severe IBS symptoms who have tried first-line measures without adequate relief
• Individuals whose standard evaluation has ruled out other conditions yet symptoms persist or fluctuate unpredictably
• Those with a history of frequent antibiotics, gastrointestinal infections, or major dietary shifts who want to understand potential ecosystem effects
• Patients interested in a data-informed approach to diet, fiber, and probiotics rather than trial-and-error alone

When Testing Might Be Most Valuable

Microbiome testing tends to be most informative:

• Before or during structured dietary interventions (e.g., low-FODMAP, fiber titration, or reintroduction phases)
• When selecting or evaluating probiotic strategies, especially if prior attempts were inconsistent
• After notable disruptions (antibiotics, gastroenteritis) to document recovery or persistent shifts
• When personalizing long-term gut health habits, recognizing that results should be interpreted with clinical context

If you are considering a stool microbiome analysis to complement your IBS diagnosis journey, you can explore what’s included in this stool microbiome analysis for a sense of the insights typically provided. Collaboration with your healthcare provider can help translate findings into practical steps.

Decision-Support: When Does Microbiome Testing Make Sense?

Guidelines for Considering Microbiome Testing

Ask the following questions when deciding whether to add microbiome profiling:

• Do I have persistent IBS symptoms despite trying standard, guideline-based approaches?
• Have alarm features been excluded and age-appropriate screening completed?
• Do I have signs that suggest dysbiosis (history of frequent antibiotics, post-infectious onset, recurrent minor infections, or unexplained symptom shifts)?
• Am I about to begin a significant dietary or probiotic intervention and want a baseline?
• Am I comfortable using results as educational context rather than definitive diagnostic answers?

Limitations and Interpretations

Microbiome tests reflect a snapshot of a dynamic ecosystem influenced by diet, stress, and medications. Different laboratories use different methods, yielding slightly different views of the same sample. Findings should not override clinical red flags or minimize the need for appropriate medical evaluation. Instead, they serve as one data layer among many—history, exam, standard labs, and your lived experience. When results align with symptoms and goals, they can reduce guesswork and make dietary or probiotic trials more targeted. For a balanced sense of what these tools can and cannot do, review the details of this personalized microbiome insights option and discuss with your clinician.

Concluding Section: Connecting Diagnosis to Personal Gut Microbiome Awareness

The Future of IBS Diagnosis: Personalized Gut Health

IBS diagnosis will likely remain symptom-based, guided by established criteria and focused exclusion of other diseases. The future lies not in a single decisive test but in better phenotyping—integrating clinical patterns with biomarkers, digital symptom tracking, and microbiome-informed context. This personalized approach acknowledges that the same symptoms can arise from different mechanisms, and that management works best when tuned to the individual rather than a generic protocol.

Empowering Patients with Knowledge

Understanding how IBS is diagnosed empowers you to participate actively in care: to ask clear questions, to recognize when limited testing is sufficient, and to know when deeper inquiry could be useful. Learning about your unique microbiome profile can complement this process by illuminating patterns that influence gas, motility, and sensitivity. While no test replaces good clinical care, informed self-awareness—about triggers, diet, stress, sleep, and microbial context—can make day-to-day decisions more confident and less trial-and-error. That is the heart of personalized gut health.

Key Takeaways

• IBS is a clinical diagnosis based on Rome criteria and IBS symptoms assessment; no single lab test confirms it.
• Targeted testing helps with ruling out other conditions such as IBD, celiac disease, infections, and microscopic colitis when suggested by history or alarm features.
• Symptoms alone rarely reveal root cause because multiple mechanisms—motility, sensitivity, immune tone, bile acids, and microbiome—can overlap.
• The gut microbiome influences gas production, motility, and immune signaling; dysbiosis may contribute to IBS for some individuals.
• Microbiome testing is not diagnostic for IBS but can provide personalized context to guide diet and probiotic strategies.
• Consider microbiome analysis when symptoms persist despite standard care, after major disruptions (e.g., antibiotics), or before structured dietary changes.
• A stepwise, individualized gastrointestinal health evaluation balances safety, efficiency, and relevance to your specific symptoms and goals.
• Shared decision-making with your clinician helps determine which tests add value and which can be safely deferred.

Frequently Asked Questions

How do doctors diagnose irritable bowel syndrome?

Doctors use symptom-based criteria (Rome IV), focusing on recurrent abdominal pain related to bowel movements and changes in stool frequency or form. They perform a targeted exam and order selective tests to exclude other conditions when alarm features or specific risks are present. IBS is a positive clinical diagnosis, not just a diagnosis of exclusion.

What tests rule out other conditions before confirming IBS?

Common tests include celiac serology in IBS-D/IBS-M, fecal calprotectin or CRP to screen for inflammation, stool tests for infections in appropriate settings, and thyroid function tests when indicated. Colonoscopy is considered for alarm features, chronic diarrhea of unclear origin, or routine cancer screening based on age and risk.

Can a stool test diagnose IBS?

No. There is no single biomarker that diagnoses IBS. Stool tests can be useful to rule out infections, check for inflammatory markers, or profile the microbiome, but they do not confirm IBS on their own. Diagnosis relies on clinical symptoms and judicious use of tests.

What are alarm features that warrant more extensive testing?

Alarm features include unintentional weight loss, rectal bleeding or black stools, anemia, persistent fever, nighttime symptoms that wake you, onset after age 50, and a family history of IBD, colorectal cancer, or celiac disease. These findings prompt further evaluation to exclude conditions other than IBS.

2-minute self-check Is a gut microbiome test useful for you? Answer a few quick questions and find out if a microbiome test is actually useful for you. ✔ Takes 2 minutes ✔ Based on your symptoms & lifestyle ✔ Clear yes/no recommendation Check if a test is right for me →

How does the microbiome relate to IBS symptoms?

The microbiome influences fermentation, gas production, motility, and immune signaling. Differences in microbial diversity, SCFA production, and gas-associated microbes have been observed in some people with IBS. While not the sole cause, these patterns can contribute to symptom profiles and inform dietary strategies.

Is SIBO the same as IBS?

No. SIBO (small intestinal bacterial overgrowth) is a distinct condition in which excess bacteria colonize the small intestine. Some symptoms overlap with IBS, and a subset of IBS-like symptoms may involve SIBO. Breath testing can be considered in selected patients, but results require careful interpretation.

When is colonoscopy recommended in suspected IBS?

Colonoscopy is generally reserved for alarm features, chronic diarrhea with unclear cause, or routine colorectal cancer screening based on age and risk factors. Typical IBS without red flags often does not require colonoscopy for diagnosis.

What is the role of bile acids in IBS-like diarrhea?

Excess bile acids in the colon can increase water secretion and motility, causing watery stools and urgency. Bile acid malabsorption is an under-recognized cause of chronic diarrhea; specialized tests or an empiric therapeutic trial may be considered when suspected.

Can microbiome testing help personalize diet for IBS?

Microbiome profiling can highlight fermentation tendencies, gas-associated microbes, or relative abundance of butyrate producers, which may inform fiber progression or consideration of a low-FODMAP approach. It does not replace clinical care but can add context for more targeted dietary trials.

What is the Rome IV criteria for IBS in simple terms?

Rome IV defines IBS as recurrent abdominal pain at least one day per week over the last three months, associated with changes in bowel habits (frequency or stool form) and related to defecation. Symptoms begin at least six months before diagnosis and other serious conditions should be reasonably excluded.

Do stress and sleep affect IBS diagnosis or symptoms?

Stress and poor sleep can amplify gut–brain signaling, increasing pain sensitivity and altering motility. They don’t determine the diagnosis, but they often influence symptom intensity, making stress management and sleep optimization valuable parts of care.

Should everyone with IBS get a microbiome test?

No. Microbiome testing is optional and most helpful when standard care hasn’t provided clarity or when you want to personalize diet and probiotic strategies. The decision should be based on your goals, symptom persistence, and comfort using results as contextual insight rather than definitive answers.

Keywords

IBS diagnosis, diagnostic criteria for IBS, IBS symptoms assessment, ruling out other conditions, functional bowel disorder testing, gastrointestinal health evaluation, Rome IV criteria, alarm features in IBS, fecal calprotectin, celiac serology, bile acid malabsorption, SIBO and IBS, methane and constipation, gut microbiome, dysbiosis, microbial diversity, SCFAs, gas production, personalized gut health, microbiome testing, stool analysis, low-FODMAP diet, butyrate-producing bacteria, gut–brain axis